Future Science Group

Find out more about working with immunogenicity as well as what the future may hold for the field in this interview with Joyce Slusser (KCAS) - http://bit.ly/2OjaOX7

We spoke to Mark Behlke, the chief scientific officer of Integrated DNA Technologies (IA, USA), about the current limitations of CRISPR/Cas9 techniques and the potential of the novel HiFI Cas9 enzyme to resolve these limitations, as shown in a sickle cell disease-causing mutation.

In line with our October focus on healthcare-associated infections, we spoke to Amy Mathers about her research on the role of hospital plumbing in the evolution and exchange of genes of drug resistance. Amy discussed her research on sink traps, toilets and wastewater, what solutions hospitals can use and antibiotic resistance in the broader context – including the role of infection prevention and control.

Find out more about the flow cytometry in this Bioanalysis Zone interview with Christoph Eberle (Charles River Laboratories), as part of our 'In the Zone' feature. You can find out more about flow cytometry on the website, at: http://bit.ly/2RuwAKi

In this podcast, Roshaine Wijayatunga, Senior Editor for Oncology at Future Science Group speaks with Barbara Moss, a Patient Ambassador for Europacolon (UK) and Bowel Cancer UK. At the age of 52, in 2006, Barbara was diagnosed with Stage IV colorectal cancer of the colon, spread to the liver, and was told she had 3–5 months to live. Barbara is now an active campaigner and an active member of several organizations in the UK and Europe. Her main wish is for patients to be able to access the medicine that they need, to have choices clearly explained and to be treated personally.

Since Zika broke into the news in 2016, new research has been uncovering more information about this virus – we spoke to Dustin Farr at the recent ASM Microbe meeting where he was presenting a poster on Zika infection in corneal cells.

Find out more about the technologies utilized in drug discovery and what the future holds for biotherapeutic drug metabolism studies in this Bioanalysis Zone interview with Kevin Ray (MilliporeSigma), as part of our 'In the Zone' feature on drug metabolism. You can find out more about drug metabolism on the website, at: https://www.bioanalysis-zone.com/2018/08/13/in-the-zone_inz_drug_metabolism/ The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the US and Canada.

As part of our focus, we present this podcast where we talk to Mark Savage (Biotransformation and ADME Scientist, Unilabs, UK). Mark introduces what biotransformation is and the technologies used to characterize biotransformation. He discusses how software tools can address certain challenges and bring forward compounds from discovery to development.

At the FENS Forum of Neuroscience (7–11 July, Berlin, Germany), we had the pleasure of speaking with Irene Tracey, who is a Professor based at the University of Oxford (UK). Irene is also the Head of the Nuffield Department of Clinical Neurosciences (Oxford, UK), which includes a multidisciplinary taskforce working to understand neuroscience from a basic discovery perspective all the way through to clinical problems. Irene’s research particularly focuses on using neuroimaging to understand pain. In this NCTalks podcast recorded at the event, Lauren Pulling (Publisher) speaks to Irene to find out more about her talk at FENS, including significant breakthroughs within the field and if we could ever have one standardized measure of pain. View more podcasts, news and exclusive interviews at www.neuro-central.com

The TAILORx study demonstrated that most women with a specific early-stage breast cancer and midrange score on the Oncotype Dx test do not need chemotherapy after surgery. These findings will spare thousands of women from the harmful effects of chemotherapy. We spoke with Andrew Paramore from Genomic Health (CA, USA)to discover insider details of the trial and what’s next for TAILORx.

Whilst at the Alzheimer’s Society Annual Conference (22–23 May, London, UK), we had the pleasure of speaking to Wendy Weidner, the Research and Policy Project Lead for Alzheimer’s Disease International, to hear more about her talk on ‘A world without dementia’. In this #NCTalks podcast recorded at the event, Sharon Salt (Editor) speaks to Wendy to find out more about the work that Alzheimer’s Disease International is carrying out in terms of dementia globally, as well as the key challenges and biggest achievements involved to date. View more podcasts, news and exclusive interviews at www.neuro-central.com

Irina Armean from the European Bioinformatics Institute discusses the gene ontology (GO) and how machine learning can play a role in evaluating protein protein interactions (PPIs).

Whilst at the Alzheimer’s Society Annual Conference (22–23 May, London, UK), we had the pleasure of speaking to Simon Lovestone, a Professor of Translational Neuroscience at the University of Oxford (UK), to hear more about his talk on ‘Dementia – Big problem; Big Data – Big solution?’ In this #NCTalks podcast recorded at the event, Sharon Salt (Editor) speaks to Simon to find out more about big data in dementia, including an overview of the talk given and how scientists can do more big data research. Listen to our podcast below to find out more. View more podcasts, news and exclusive interviews at www.neuro-central.com

At the American Academy of Neurology’s 70th Annual Meeting (21–27 April, CA, USA), we spoke to Aleksandar Videnovic, a neurologist at Massachusetts General Hospital (MA, USA), about what a career in clinical trials involves. Aleksandar is also an Associate Professor of Neurology at Harvard Medical School (MA, USA). In this #NCTalks podcast recorded at the event, Lauren Pulling (Publisher) speaks to Aleksandar to learn more about how to start a career in clinical trials, common challenges involved, rewarding aspects and advice for those thinking of starting a career in clinical trials. Listen to our podcast below to find out more. View more podcasts, news and exclusive interviews at www.neuro-central.com

In this latest edition of NCTalks, Sharon Salt (Editor) speaks with Jens Kuhle, a neurologist at the University Hospital Basel, Switzerland. Jens is the head of the multiple sclerosis (MS) center at the hospital and runs a research group called ‘Translational Biomarkers and Biobanking’. In this podcast, Jens speaks about monitoring MS using blood neurofilament light protein and how this could impact the way we monitor and treat MS. Jens also discusses how he overcame the hurdle of measuring neurofilament in the blood and what the next steps are for his team.

In this latest edition of NCTalks, Lauren Pulling (Publisher) speaks to Giovanni Baranello, a Pediatric Neurologist working at the Carlo Besta Neurological Institute (Milan, Italy). Giovanni is the principal investigator of the FIREFISH clinical trial, a preliminary study investigating the safety and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy. In this podcast recorded at the American Academy of Neurology’s 70th Annual Meeting (April 21–27, CA, USA), Giovanni speaks about the FIREFISH trial and the mechanisms of RO7034067. Giovanni also discusses part II of the study and what the next steps include, and where the field could be in 5–10 years’ time. View more podcasts, news and exclusive interviews at www.neuro-central.com

As part of our Spotlight, we present this interview with Cory Muraco who discusses his interest in chromatography, the technologies he uses and his top three tips for chromatographic method development.

As part of our focus, In the Zone: old vs new technologies, we present this podcast where we talk to Franklin Spriggs (Director of Large Molecule Services, KCAS) about his experience with investing in different technologies, and the key questions that need to be addressed when making any decision between different technologies. To find out more, visit: http://bit.ly/2rwG1fZ

Last week we had the pleasure of attending the American Academy of Neurology’s 70th Annual Meeting (April 21–27, CA, USA), where we spoke to Robert Fox, from the Mellen Center for Multiple Sclerosis at the Cleveland Clinic (OH, USA), about the Phase II SPRINT-MS trial of ibudilast in progressive multiple sclerosis. In this #NCTalks podcast recorded at the event, Lauren Pulling (Publisher) speaks to Robert, who is the Protocol Principal Investigator in the trial, to learn more about the current landscape that led to this research and potential treatment regimens. Listen to our podcast below to find out more. View more podcasts, news and exclusive interviews at www.neuro-central.com

Whilst at the Alzheimer’s Research UK (ARUK) Conference (20–21 March, London, UK), Lauren Pulling (Publisher) spoke to Giovanna Malluci, a Professor of Clinical Neurosciences at the University of Cambridge (UK) and Consultant Neurologist specializing in dementia. Giovanna is also the Associate Director of the Cambridge Center of the UK Dementia Research Institute (DRI). In this #NCTalks podcast recorded at the ARUK Conference, Giovanna speaks about translating innovation from lab to clinic across the UK DRI, promising dementia research themes and what the dementia research landscape could look like in 10 years' time. View more podcasts, news and exclusive interviews at www.neuro-central.com